Scientific Publications, Posters & Presentations
Scientific Publications, Posters & Presentations
Publications
Publications that have resulted from Ardea Biosciences’ proprietary research programs or through research collaborations with other biotechnology or pharmaceutical companies will be posted below once available. The links for the articles go to subscription-based sites and may require a fee to view the article.
Presentations
Posters
 |
Safety and Uric Acid Lowering Effect in Humans Following Multiple Doses of RDEA806, a Novel Prodrug for the Potential Treatment of Hyperuricemia |
 |
Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans Following Multiple Doses of its Pro-drug, RDEA806 |
 |
RDEA119, A Selective MEK 1/2 Inhibitor Ameliorates Experimental Arthritis |
 |
RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties |
 |
RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies |
 |
A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses |
 |
RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses |
 |
An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins |
 |
RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer |
 |
The Discovery of RDEA806, a Potent New HIV NNRTI in Phase 1 Clinical Trials |
 |
RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance |
 |
Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers |
 |
RDEA806, A Potent Non-Nucleoside Reverse Transcriptase Inhibitor
with Less Potential for Drug-Drug Interactions |
